Atomo Diagnostics Limited Overview
Atomo Diagnostics is a micro-cap Australian medical device company that designs, makes and sells integrated, blood-based lateral-flow rapid diagnostic test (RDT) devices for professional point-of-care and self-testing. It has two revenue engines. The first is its own finished tests, chiefly the WHO-prequalified, TGA-approved and CE-marked Atomo HIV Self-Test, sold through Viatris (formerly Mylan) into Global Fund–financed low- and middle-income country (LMIC) programmes, through NFLD in Europe, and through pharmacies and government programmes in Australia and New Zealand. The second is an OEM "Atomo inside" business supplying its patented all-in-one Pascal cassette to diagnostics partners. The flagship OEM customer is Lumos Diagnostics, whose FebriDx bacterial-versus-viral test received US FDA CLIA waiver in March 2026 on the Pascal platform. With FY2026 revenue of A$5.3m (+41%), a narrowing loss, no debt and a pipeline spanning active syphilis, liver function (ALT) and ferritin, Atomo is a sub-scale but differentiated device-platform play. It is in a leadership transition and depends on regular equity raises.
Company's own description (FY2026 Annual Report and Results Overview). The FY2026 Directors' Report defines the group's principal activity as "the development and sale of medical devices." The FY2026 Results Overview calls Atomo "a commercial stage diagnostic company with a growing revenue base from sales of approved professional and self-test point-of-care tests (POCT) across global markets." It says Atomo's solutions deliver usability and reliability that enable decentralised testing. The company describes two businesses:
-
Atomo Point of Care Test (POCT) Diagnostic Products. Blood-based rapid tests sold into professional-use and self-test channels globally. The stated focus is a pipeline of "high value, reimbursed diagnostic products for decentralised professional testing."
-
Point of Care Test Technologies (OEM Business). Partner sales driven by an FDA-approved, CLIA-waived test (Lumos FebriDx). Atomo supplies an integrated proprietary all-in-one device (Pascal) to partners seeking better usability and performance for blood-based POCT, plus "additional technologies that can integrate with the client's own cassette" (the Florey clip-in device).
The company's ASX boilerplate describes it as an Australian-headquartered medical device company supplying integrated RDT devices to the global diagnostic market. Its patented devices simplify testing, improve usability and improve reliability for point-of-care and at-home testing.
Business model and revenue model. Atomo generates revenue in four reported lines (FY2026 Annual Report, Note 3):
By nature, revenue is overwhelmingly product sales. Sale of goods was A$5.23m (98.0%) in FY2026. Services, meaning development and licence fees recognised over time, were A$0.11m (2.0%). There is no subscription revenue. Licensing revenue is episodic: FY2025 included roughly A$340k of one-off licence fees. In the OEM channel, Atomo is paid a transfer price for each Pascal cassette. Management describes Atomo as receiving "a percentage portion of the proceeds based on the transfer price of Pascal" for each FebriDx test sold to PHASE Scientific (FY2026 Results Overview).
The P&L is also materially supported by non-revenue government income. FY2026 other income was A$2.23m, comprising the R&D tax rebate (A$1.26m), CRC-P grant income for the Active Syphilis test (A$0.89m) and interest (A$0.08m). That equals 42% of revenue.
Value-chain position. Atomo sits at the device design and manufacturing layer of the rapid-diagnostics value chain:
-
It designs and patents the integrated device: lancet, blood collection, buffer delivery and test strip housed in one cassette.
-
It qualifies tooling, including high-cavitation injection moulds now being qualified, and runs proprietary blister packaging machines. Blister Machine #2 was relocated to an Atomo-operated facility in Sydney in FY2026.
-
It performs finished-test assembly and packaging at its South African branch.
-
It relies on third-party manufacturers for certain inputs (FY2026 risk disclosures).
-
For own products, it holds regulatory registrations (TGA, CE/IVDD/IVDR, WHO PQ) and sells through distributors such as Viatris, NFLD, pharmacy wholesalers and government programmes.
-
For OEM products, the partner (e.g., Lumos) owns the assay and regulatory file, and Atomo is the "critical supplier" of the device.
Customer types. Global health procurement intermediaries (Viatris, funded by the Global Fund); European consumer-health distributors (NFLD; historically supplying retailers such as Boots and Tesco); Australian and New Zealand pharmacies and wholesalers (Chemist Warehouse online, CDC in New Zealand); Australian government-funded programmes (e.g., distribution with NAPWHA, the National Association of People with HIV Australia); and IVD companies buying OEM devices (Lumos Diagnostics, Chromacare, an unnamed UK company, and two new OEM customers from January 2026). Customer concentration is extreme: five customers accounted for 92.0% of FY2026 revenue (FY2025: 72.5%). The largest single customer ("Customer E") accounted for 36.2%. The Annual Report does not name it, but given the nine-fold rise in Lumos orders it is likely Lumos; that attribution is an inference.
End-markets served. (i) HIV self-testing and professional HIV testing (LMIC public health, European retail, Australia/NZ pharmacy and government); (ii) US decentralised professional testing (urgent care, physician office) via CLIA-waived OEM products; (iii) emerging sexual health (active syphilis), liver function monitoring (ALT) and iron deficiency (ferritin); (iv) historically, COVID-19 antibody testing (FY2020–FY2022) and female health/pregnancy.
Independent characterisation. Atomo is best understood as a device-platform company with a small captive finished-goods franchise. Its intellectual property is ergonomic and mechanical, not biochemical: it solves the user-error problem in finger-stick blood testing. The economic proof point is the FDA CLIA waiver for FebriDx. US trials showed more than 99% concordance between trained and untrained users, and management states the waiver relied on Pascal's performance. That regulatory precedent is arguably Atomo's most valuable asset, because it gives future partners a predicate path into the CLIA-waived and self-test channels. CLIA waiver can expand a rapid blood test's addressable market more than ten-fold (company claim). The business remains sub-scale, however: revenue of A$5.3m, gross margin of 35%, and statutory operating cash burn of A$3.4m in FY2026. Volumes are lumpy and tied to partner order cycles and donor-funded tenders.
Strategy
Stated strategic themes (FY2026 Annual Report, "Likely developments"; FY2026 Results Overview).
-
Grow HIV self-testing globally. Continue rollout in developed markets (Europe, Australia, New Zealand) and LMIC programmes. Targets: Australian pharmacy count 6× and NZ 8× over three years.
-
Expand the POC cassette supply (OEM) business, especially in the US. Use the FebriDx CLIA waiver as "a predicate pathway for new Diagnostics partners" seeking CLIA-waived and self-test access. This includes promoting Pascal to US test developers.
-
Grow development services. Atomo is paid to develop custom products and solutions for partners.
-
Improve operating margins. Bring blister manufacturing in-house and qualify high-cavitation tooling to reduce COGS.
-
Build the own-product pipeline. Active Syphilis (clinical trials from early CY2027) and ALT Liver (partnering in FY2027), using non-dilutive grants and selective in-licensing "to support lower-cost development and go to market."
-
Capital discipline. "Remaining focused on conserving capital over the medium term."
-
Leadership repositioning. "Strategic priority shifts from foundation-building to scale: accelerating adoption, expanding partnerships and maximising the value of Atomo's differentiated platform" (FY2026 Results Overview, "New chapter").
Management's virtuous-cycle framing: revenue growth → improved operating leverage → reinvestment in R&D → broader product portfolio → long-term revenue growth and enterprise value. Management expects revenue "to cover most non-research operating costs."
Initiatives announced in the last 24 months.
Sustainability/ESG commitments. None quantified. The board is "considering on an ongoing basis" a climate-risk response.
Medium-term financial targets/guidance. No quantitative revenue, margin or EBITDA guidance has been issued. Qualitative guidance: "We expect the underlying revenue trajectory to continue into FY27 and beyond." When announcing the March 2026 raise, the company stated it was "funded through early 2028." That statement assumed a raise of up to A$4.0m; only ~A$3.05m was raised before shortfall placement.
Products & Services
Atomo markets its devices under the "AtomoRapid" umbrella. Products are organised below by the company's two businesses. Pricing is not publicly disclosed for any product.
5A. Atomo POCT Diagnostic Products (own finished tests)
| Product | Description and key capabilities | Target customer / channel | Regulatory status | Launch / latest | Commercial notes |
|---|---|---|---|---|---|
| Atomo HIV Self-Test (flagship) | Integrated all-in-one finger-stick blood RDT detecting HIV-1/2 antibodies; built-in lancet, blood collector and buffer; designed for untrained lay users | LMIC public health via Viatris (Mylan brand) funded by the Global Fund; Europe via NFLD (historically Boots and Tesco in the UK); Australia via pharmacies (196 active as at July 2026), Chemist Warehouse e-commerce (Oct 2025) and government-funded programmes including NAPWHA; New Zealand pharmacies (73 activated) and CDC wholesaler | WHO prequalified; TGA approved (described pre-IPO as the only TGA-approved HIV self-test); CE marked | Launched South Africa late 2016; ongoing | FY2026 HIV revenue A$2.84m (+21%). NAPWHA demand +275% over 24 months. Targets: Australian pharmacies 6× and NZ pharmacies 8× over 3 years (FY2026 Results Overview). |
| AtomoRapid HIV 1&2 (professional use) | Same integrated platform for clinician point-of-care HIV screening | Clinics, community testing, Australia and Europe | TGA approval Nov 2020; CE marked | Australian launch early CY2021 | Revenue reported within point-of-care tests; not separately disclosed |
| Active Syphilis Test (pipeline) | Rapid blood test intended to distinguish active from prior syphilis infection on the Pascal format; optimised for self-testing. Company states sensitivity above 85% for active syphilis detection is market-leading. | Sexual health clinics, public health buyers, existing HIV self-test channels | Pre-registration. Development and initial verification complete; technology transfer to manufacturing Q4 FY2026–Q1 FY2027; clinical trials from early CY2027; initial regulator engagement completed | Targeted post-CY2027 trials | Funded partly by A$2.44m CRC-P grant (A$0.84m held as deferred grant revenue at 30 June 2026). South Africa assembly accreditation being extended to syphilis tests. |
| ALT Liver Function Test (pipeline) | Rapid test measuring alanine aminotransferase (ALT) for liver damage | Initial use cases: monitoring patients on drugs at risk of causing liver injury (DILI), clinical-trial monitoring, doctor-prescribed at-home monitoring, fatty liver disease screening | Early development; exclusive in-licence from an undisclosed licensor (Q2 FY2026) | Development commenced FY2026 | Seeking pharma/CRO/commercial partners and government funding in FY2027 |
| Tests under consideration | Stroke (acute neurological triage), HCV, HBV, HIV 4th generation, cardiac | Professional decentralised markets | Concept / commercial assessment | — | Subject to commercial assessment (FY2026 Results Overview) |
| AtomoRapid COVID-19 antibody test (legacy) | Blood-based COVID-19 IgG/IgM antibody test | Supplied via NG Biotech (France/UK) and Access Bio (US) | TGA approved Aug 2020 | 2020–2022 | Drove FY2021–FY2022 revenue; demand ended post-pandemic |
| Female health / early pregnancy (legacy / partner) | Application cited in company boilerplate | Consumer | — | — | — |
5B. Point of Care Test Technologies (OEM business)
| Platform / product | Description and key capabilities | Target customer | Status | Commercial notes |
|---|---|---|---|---|
| Pascal integrated cassette (flagship OEM device) | Patented all-in-one cassette integrating lancet, blood sampling, buffer delivery and partner's test strip. Validated in US clinical trials (FebriDx) with more than 99% concordance between trained and untrained users. | IVD companies with lateral-flow assays seeking CLIA waiver or self-test claims | Commercial | FY2026 OEM revenue A$2.15m (+209%). Atomo is exclusive licensor, manufacturer and supplier of Pascal for FebriDx. Supply arrangement with Lumos runs to June 2031. |
| — Lumos FebriDx (on Pascal) | Partner's host-response test differentiating bacterial from non-bacterial (viral) acute respiratory infection | US urgent care and decentralised reimbursed professional testing | FDA CLIA waiver granted (announced 27–30 March 2026) | FY2026 Pascal orders for FebriDx of ~A$1.9m, nine-fold increase on FY2025. Lumos–PHASE contract valued at up to ~US$316–317m of FebriDx revenue over six years, subject to MOQs. At the CLIA waiver, Atomo said the agreement points to Pascal revenue of ~US$3.4m (basis per 30 March 2026 announcement). |
| — Chromacare ferritin test (on Pascal) | Rapid test for iron levels (iron deficiency screening), professional and at-home | Canadian partner Chromacare | Validation / registration; Chromacare interested in a US CLIA waiver using Pascal FebriDx as predicate | Initial order ~A$170k in FY2026; long-term supply agreement anticipated early FY2027 |
| — UK customer novel test (on Pascal) | Undisclosed novel rapid test addressing a large unmet clinical need in professional settings | Unnamed UK company | Validation / registration | 20,000 Pascal units ordered in FY2026; commercial supply agreement anticipated early FY2027 |
| — Two new OEM customers (Jan 2026) | Undisclosed applications | Undisclosed | Orders completed by Q4 FY2026 | Company says these support long-term supply agreements anticipated early FY2027 |
| Florey clip-in device | Add-on technology that integrates with a client's own cassette to turn it into a user-friendly blood-based POCT system | IVD companies with existing cassettes | Presented at two US POC diagnostics conferences (Oct 2025) | No disclosed revenue |
| Development services | Paid development of custom products and solutions using Atomo technology | Partners | Ongoing | Development and licence fees: A$0.54m in FY2025 (incl. ~A$340k one-off licences); A$0.11m in FY2026 |
Financial Narrative
Data provenance. FY2025 and FY2026 figures are from the audited FY2026 Annual Report. FY2022–FY2024 income statement data are from the Kalkine/TradingView aggregator (based on annual reports). FY2024 net loss, EPS and closing equity are cross-checked to the FY2026 Annual Report (statutory performance table and statement of changes in equity). Blank cells = not publicly disclosed in sources reviewed. EBITDA rows are labelled by basis. The aggregator reports FY2025 cost of revenue of A$2.00m and gross profit of A$1.79m, while the audited FY2026 Annual Report comparatives show A$1.87m and A$1.92m; the audited figures are used and the discrepancy is noted.
Income statement
Notes: FY2024 underlying EBITDA of approximately -A$4.5m is drawn from a third-party summary of the company's FY2026 historical EBITDA chart (Stockwire). FY2026 statutory operating loss = loss before tax (A$3.51m) less finance costs (A$0.015m). Weighted average shares were 647.1m in FY2025 and 827.3m in FY2026.
Margins and growth
Revenue CAGR. FY2022 to FY2026 (4 years): -18.9% per year, distorted by the COVID peak in FY2022. FY2023 to FY2026 (3 years): +28.0% per year. FY2021 to FY2026 (5 years, from A$6.72m): -4.5% per year.
Commentary. FY2022 was a COVID-driven peak, with revenue of A$12.3m from antibody test devices supplied to partners. FY2023 brought the cliff: revenue fell 79% to A$2.5m, gross margin compressed to 26% on under-absorbed fixed costs, and the net loss widened to A$10.0m. FY2024 to FY2026 shows a deliberate three-year restructuring. Overheads were cut every year. Operating expenses fell a further ~A$0.64–0.78m (about 9%) in FY2026, with professional fees nearly halved from A$0.95m to A$0.49m and employee costs down 12% to A$2.88m. The net loss narrowed from A$6.85m to A$4.97m to A$3.51m.
The FY2026 inflection is revenue-led: +41%, with OEM revenue tripling on Lumos FebriDx orders. But mix worked against margin. Low-priced Global Health HIV volumes and the absence of FY2025's one-off licence income pushed gross margin back to 35%. The "underlying EBITDA" improvement to -A$2.06m benefits materially from a 47% increase in other income (R&D rebate plus grant). Excluding other income, the operating loss before D&A would be roughly A$4.3m, broadly unchanged from FY2025's roughly A$4.9m on the same basis. That is an analyst calculation from statutory lines. The quality of the improvement is therefore mixed: real revenue traction, but not yet operating leverage on product gross profit.
Balance sheet
Commentary. The balance sheet is clean but small. There are no borrowings and no financing facilities (Note 21), and the company remains "debt free." Intangibles are being amortised down; no additions were made in FY2026, and A$0.80m of development costs were impaired historically. PP&E fell to A$0.34m as plant reached the end of its depreciable life, with A$7.2m gross plant against A$7.1m accumulated depreciation. Capacity investment (high-cavitation moulds, the second blister line) is therefore likely to require capex in FY2027.
Receivables almost doubled to A$3.22m. Within this, trade receivables rose to A$1.84m, 95% aged 0–30 days, reflecting a strong Q4 sales quarter, and the R&D rebate receivable was A$1.08m. Cumulative losses of A$68.5m against A$75.8m contributed capital show the extent of value consumption since founding. Unrecognised tax losses have a tax effect of A$9.34m.
Cash flow
Commentary. Operating cash burn worsened in FY2026 (-A$3.37m versus -A$1.96m) even as the P&L loss narrowed. Three factors drove this: (i) working capital build, with receivables up A$1.62m and inventory up A$0.32m; (ii) lower customer receipts, because FY2025 had benefited from collections and A$1.07m of upfront grant cash recorded as deferred revenue; and (iii) a decline in deferred revenue (-A$0.23m). Management's own presentation frames total cash receipts as A$10.2m, but that figure includes A$4.0m of equity proceeds. Funding has come entirely from equity: A$1.65m in FY2025 and A$4.06m in FY2026. At the FY2026 operating burn rate, year-end cash of A$3.71m represents roughly 13 months of runway before any working-capital release (analyst calculation).
Ratios (analyst calculations from audited figures; FY2025 ROA uses year-end assets because FY2024 total assets were not available)
ROIC, net debt/EBITDA and interest coverage are not meaningful: the company is loss-making, has net cash, and its only interest cost is lease interest of A$14.7k. The long cash conversion cycle reflects raw material stockholding (A$1.73m of the A$1.97m inventory is raw materials) relative to a small cost base. The FY2026 DSO is inflated by Q4 revenue of A$2.3m.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Product line revenue (AUD Mn)
| Product line revenue (AUD Mn) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Point-of-care tests (HIV finished tests) | — | 2.349 | 2.840 |
Point-of-care technology (OEM / Pascal) | — | 0.695 | 2.151 |
Development and licence fees | — | 0.544 | 0.106 |
Other revenue | — | 0.204 | 0.237 |
Total revenue | 4.090 | 3.792 | 5.334 |
Product line YoY growth and mix (%)
| Product line YoY growth and mix (%) | FY2025 mix | FY2026 mix | FY2026 YoY growth |
|---|---|---|---|
Point-of-care tests (HIV) | 62.0 | 53.3 | 20.9 |
Point-of-care technology (OEM) | 18.3 | 40.3 | 209.4 |
Development and licence fees | 14.3 | 2.0 | -80.5 |
Other revenue | 5.4 | 4.4 | 16.2 |
Total | 100.0 | 100.0 | 40.6 |
Group Entities
| Entity | Country | Ownership | Likely function (analyst characterisation) |
|---|---|---|---|
Atomo Diagnostics Limited | Australia | Parent (listed) | Holding, HQ, IP, R&D |
Atomo Australia Pty Limited | Australia | 100% | Operating entity |
Atomo South Africa (branch of Atomo Australia Pty Ltd) | South Africa | 100% | Finished test assembly and packaging; warehouse |
Atomo Limited | United Kingdom | 100% | European commercial presence |
Atomo US Inc. | United States | 100% | US presence |
Atomo Operations US LLC | United States | 100% | US operations |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (AUD Mn) | 12.34 | 2.54 | 4.09 | 3.79 | 5.33 |
Cost of sales (AUD Mn) | 8.09 | 1.88 | 2.65 | 1.87 | 3.45 |
Gross profit (AUD Mn) | 4.25 | 0.67 | 1.44 | 1.92 | 1.88 |
Other income incl. R&D rebate and grants (AUD Mn) | — | — | — | 1.52 | 2.23 |
Depreciation and amortisation (AUD Mn) | 2.00 | 1.89 | 1.66 | 1.58 | 1.43 |
EBIT, aggregator basis (AUD Mn) | -5.69 | -11.21 | -7.78 | -5.84 | — |
Operating loss before finance costs, statutory (AUD Mn) | — | — | — | -4.95 | -3.50 |
Underlying EBITDA, company-reported (AUD Mn) | — | — | -4.50 | -3.38 | -2.06 |
Pre-tax income (AUD Mn) | -5.71 | -9.96 | -6.85 | -4.97 | -3.51 |
Net income (AUD Mn) | -5.72 | -9.96 | -6.85 | -4.97 | -3.51 |
EPS basic (AUD cents) | — | — | -1.08 | -0.768 | -0.425 |
EPS diluted (AUD cents) | — | — | -1.08 | -0.768 | -0.425 |
Dividends per share (AUD cents) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue growth YoY (%) | 83.6 | -79.4 | 61.0 | -7.3 | 40.6 |
Gross margin (%) | 34.4 | 26.4 | 35.2 | 50.6 | 35.2 |
Underlying EBITDA margin (%) | — | — | -110.0 | -89.2 | -38.6 |
Net margin (%) | -46.4 | -392.1 | -167.5 | -131.1 | -65.9 |
Balance Sheet and Share Count (M)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Total assets (AUD Mn) | — | 9.28 | 10.83 |
Cash and equivalents (AUD Mn) | 3.69 | 3.22 | 3.71 |
Trade and other receivables (AUD Mn) | — | 1.69 | 3.22 |
Inventories (AUD Mn) | — | 1.65 | 1.97 |
Short-term debt incl. current leases (AUD Mn) | — | 0.16 | 0.26 |
Long-term debt incl. non-current leases (AUD Mn) | — | 0.03 | 0.12 |
Borrowings excl. leases (AUD Mn) | — | 0 | 0 |
Net debt incl. leases (AUD Mn, negative = net cash) | — | -3.03 | -3.34 |
Total equity (AUD Mn) | 10.08 | 6.98 | 7.71 |
Goodwill (AUD Mn) | — | 0 | 0 |
Intangible assets (AUD Mn) | 2.07 | 1.64 | 1.22 |
Working capital, current assets less current liabilities (AUD Mn) | — | 4.40 | 5.97 |
Accumulated losses (AUD Mn) | 60.09 | 64.95 | 68.47 |
Shares on issue (M) | — | 739.1 | 902.4 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Receipts from customers (AUD Mn) | — | — | — | 5.14 | 4.62 |
R&D rebate and government grants received (AUD Mn) | — | — | — | 1.83 | 1.54 |
Operating cash flow (AUD Mn) | — | — | — | -1.96 | -3.37 |
Capex, PP&E (AUD Mn) | — | — | — | 0.03 | 0.04 |
Free cash flow (AUD Mn) | — | — | — | -1.99 | -3.40 |
Lease repayments (AUD Mn) | — | — | — | 0.19 | 0.24 |
Net equity raised (AUD Mn) | — | — | — | 1.65 | 4.06 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2025 | FY2026 |
|---|---|---|
ROE (%) — net loss / average equity | -58.3 | -47.9 |
ROA (%) | -53.6 | -35.0 |
Current ratio (x) | 3.03 | 3.04 |
Debt (leases) / equity (x) | 0.03 | 0.05 |
Asset turnover (x) | 0.41 | 0.53 |
Days sales outstanding (trade receivables) | 60 | 126 |
Days inventory outstanding | 322 | 208 |
Days payables outstanding | 74 | 111 |
Cash conversion cycle (days) | 308 | 223 |
Currency-denominated financial assets (AUD Mn)
| Currency-denominated financial assets (AUD Mn) | FY2025 | FY2026 |
|---|---|---|
US dollar | 0.48 | 0.88 |
South African rand | 0.25 | 0.84 |
Pound sterling | 0.21 | 0.26 |
New Zealand dollar | 0.01 | 0.03 |
Euro | 0.01 | 0.01 |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
IPO price (Apr 2020) | A$0.20 | StartupDaily |
Post-IPO high | A$0.565 (20 Apr 2020) | Biotech Daily |
Latest observed price | ~A$0.018 (late Aug / early Sep 2026) | InvestSMART |
Change since IPO | approx. -91% | Calculated |
52-week range | ~A$0.02–0.06 (rounded) | Halo Technologies |
Price at CLIA waiver / placement announcement | A$0.040 (30 Mar 2026); placement priced at A$0.033 | InvestSMART; ASX |
Price change since placement | approx. -45% from A$0.033; -55% from A$0.040 | Calculated |
Fiscal-year share price change (%) | FY2024 | FY2025 |
Share price change per Remuneration Report | 14 | -44 |
Valuation Multiples
| Multiple | Atomo |
|---|---|
P/E | Not meaningful (loss) |
EV/EBITDA | Not meaningful (negative EBITDA) |
EV/Sales (FY2026) | ~2.4x |
P/B (FY2026 equity A$7.71m) | ~2.1x |
Price/NTA | Net tangible assets per share per Appendix 4E reported as 0.72 cents (unit as published) |
Share Price & Returns
| Date | Type | Price (AUD) | Shares (M) | Gross proceeds (AUD Mn) | Attaching options |
|---|---|---|---|---|---|
Apr–Aug 2025 (incl. FY2026 tranches) | Placement and SPP shortfall | 0.0185 | 71.1 (FY2026 portion) | 1.29 (FY2026 portion) | 1:1 at A$0.04, 3-year expiry |
Mar–Apr 2026 | Placement | 0.033 | 90.9 | 3.00 | 1:2 at A$0.045, 2.5-year expiry |
May 2026 | SPP | 0.033 | 1.35 | 0.04 | 1:2 at A$0.045 |
Analyst Conclusions
Management guidance. No quantitative guidance. Management expects the underlying revenue trajectory "to continue into FY27 and beyond," driven by HIV, OEM/Pascal and new products. It expects revenue to cover most non-research operating costs. Near-term milestones it has flagged: long-term Pascal supply agreements with the UK customer, Chromacare and two new OEM customers (early FY2027); Active Syphilis clinical trials (early CY2027); ALT partnering (FY2027); qualification of capacity and COGS projects. Consensus growth expectations: not publicly available.
Bull case.
-
FebriDx becomes a high-volume US product. The Lumos–PHASE contract is valued at up to ~US$316m over six years with MOQs, and every test needs a Pascal cassette. FY2026 Pascal orders already rose nine-fold to ~A$1.9m before a full post-waiver year. A ramp could make OEM the majority of revenue with recurring, contract-backed volume to 2031.
-
The CLIA predicate converts into a multi-partner platform. Chromacare, the UK customer and two new OEM customers could sign supply agreements in early FY2027. Each additional waived or self-test product on Pascal adds volume with minimal Atomo R&D cost, improving mix and gross margin.
-
Operating leverage plus cheap valuation. At an EV of ~A$13m (~2.4x FY2026 sales), a debt-free company growing revenue 41%, narrowing underlying EBITDA losses 39%, and moving blistering in-house could re-rate sharply if it nears EBITDA breakeven within two years.
Bear case.
-
Funding treadmill and dilution. FY2026 operating burn of A$3.37m roughly equals year-end cash of A$3.71m. The March 2026 "funded through early 2028" claim assumed A$4.0m, but the SPP raised just A$44.5k. With 230m options largely out of the money and the share price ~45% below the latest placement, further raises at depressed prices look likely.
-
Concentration and margin fragility. Five customers make up 92% of revenue, and gross margin fell from 51% to 35%. FebriDx volumes depend on Lumos (itself a small-cap) and PHASE executing a US launch, and LMIC HIV volumes depend on donor funding. A delay at either could reverse FY2026's growth.
-
Leadership and governance gap. The founder-CEO and chief technologist left abruptly in August 2026. The interim CEO's term is six months, the board has three members, and the only committee includes the CEO. Execution risk is elevated just as the company tries to convert partners into contracts.
Key catalysts and monitorables (next 12 months).
Concluding analyst verdict.
Atomo Diagnostics exits FY2026 in better commercial shape than at any point since the COVID-19 boom. Revenue rose 41% to A$5.3m, the OEM line tripled, and the net loss fell for a third straight year to A$3.5m. The FDA's March 2026 CLIA waiver for Lumos's FebriDx, granted on the strength of Pascal's lay-user performance, is a genuine strategic asset. It turns Atomo from a one-product HIV self-test vendor into a credentialled device platform with a contracted US volume channel to 2031 and a regulatory predicate that third parties are already exploring.
The financial base remains fragile, however. Gross margin fell to 35% as low-priced global health volumes grew. Statutory operating cash burn increased to A$3.4m, close to the A$3.7m cash balance. Almost half of "underlying EBITDA" improvement came from R&D rebates and grant income rather than product economics. Five customers generate 92% of sales. The retail shareholder base largely declined the May 2026 SPP, and the share price trades well below the March placement. Into this the board has introduced a founder-CEO transition, with an interim leader on a six-month term.
Our synthesis is that Atomo is a high-risk, binary-leaning micro-cap whose equity value hinges on three verifiable events over the next 12 months: (1) observable FebriDx volume ramp through Lumos and PHASE; (2) conversion of at least two OEM validation customers into signed supply agreements; and (3) a credible permanent CEO and financing on terms that limit dilution. If all three occur, an EV of ~2.4x trailing sales for a debt-free, 40%-growth device platform looks undemanding. If FebriDx stalls or financing is struck at distressed prices, dilution will likely absorb much of the operational progress. Investors should treat the stock as an option on Pascal's platform economics, size positions accordingly, and track quarterly 4C cash flows and the Lumos order book as the primary indicators.
Source list (primary documents first)
-
Atomo Diagnostics, 2026 Appendix 4E and Annual Report (FY ended 30 June 2026), released 31 August 2026
-
Atomo Diagnostics, FY26 Results Overview presentation, 31 August 2026
-
Atomo Diagnostics, ASX announcement "Managing Director & CEO Transition," 19 August 2026
-
Atomo Diagnostics, Quarterly Activities / Appendix 4C reports: 29 October 2025, 28 January 2026, 28 April 2026, 23 July 2026
-
Atomo Diagnostics, H1 FY26 Appendix 4D, Half Year Report and Results Presentation, 26 February 2026
-
Atomo Diagnostics, ASX announcements: 15 January 2026 and 30 January 2026 (HIV Self-Test orders); 25 March 2026 (price query response); 30 March 2026 (FebriDx CLIA waiver; capital raise); 17 April 2026 (Aware Letter response); 15 May 2026 (SPP results); 29 October 2025 (commercial progress)
-
Atomo Diagnostics, FY2025 results call transcript (via financialfilings.com)
-
Kalkine / TradingView financial summary (FY2021–FY2025); Kalkine company report (2020)
-
InvestSMART announcement summaries and share price data; Market Index; Simply Wall St ownership data; multiples.vc; Investing.com; Halo Technologies; MarketScreener; IBISWorld
-
StartupDaily, Biotech Daily, SmallCaps and Stockhead (IPO-era history, 2020); Stockwire and ShareCafe (FY2026 coverage); TipRanks (board changes)
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Independence | Background and education | Committee | Shares / options held |
|---|---|---|---|---|---|---|
Patrick Cook | Non-Executive Chair | Director 2 May 2025; Chair 9 Sep 2025 | Independent | 35+ years as senior executive in medical devices and POC diagnostics; former NED/Chair of Workplace Drug Testing Australasia and eWaste Connection; former board member, Prostate Cancer Foundation of Australia (Qld); FAICD; degrees in Science and Marketing | Audit and Risk Committee member | 717,909 shares; 1,940,541 options |
Dr Cheri Walker | Executive Director and Interim CEO | Director 15 Nov 2022; Interim CEO 19 Aug 2026 | Not independent (executive since 19 Aug 2026) | 25+ years in life sciences and diagnostics; former CEO Zeta Corporation; founder-CEO Rhinostics; CFO Kailos Genetics; senior roles at Abcam, Charles River Labs, Qiagen and Life Technologies (now Thermo Fisher); BA Biology (Swarthmore College); PhD Human and Molecular Genetics (Baylor College) | Audit and Risk Committee member (Chair until 19 Aug 2026) | Nil shares; 1,000,000 options |
Anthony May | Non-Executive Director | 2 May 2025 | Independent | Director roles at Hoechst (Germany), Microgenics (USA), Fisher Scientific and Thermo Fisher Scientific; experience across public and private pathology and IVD sales/management; member of the Australasian Association for Clinical Biochemistry and Laboratory Medicine; BSc | Chair, Audit and Risk Committee | 540,541 shares; 1,240,541 options |
Executive Leadership Team
| Name | Title | Tenure | Prior roles / notes |
|---|---|---|---|
Dr Cheri Walker | Interim CEO (6-month initial term, extendable by 6 months) | Since 19 Aug 2026 | See above. Annualised interim CEO remuneration A$445,000 plus A$50,000 director fee; 90-day notice. |
Chandra Sukumar | Chief Operating Officer | Since 31 Oct 2016 | Base A$265,000 plus super; STI up to 30% of base |
Mathew Watkins | Company Secretary | Since 9 Jun 2024 | Chartered Accountant; Australian Market Lead, Vistra Australia |
CFO / finance lead | Not a KMP; FY2025 results presented by "Suzy" (surname not disclosed) | — | — |
John Kelly (former) | Co-founder, MD and CEO | 1 Apr 2010 – 19 Aug 2026 | Ex-COO Unilife (2005–08); ResMed New Product Implementation Group lead; CR Bard Europe. Hons BEng Mechanical Engineering (Liverpool); MSc Manufacturing Systems Engineering (Queen's University Belfast); Executive MBA (University of Sydney). NED of Tetratherix Limited. Holds 74,111,870 shares (~8.2% of shares on issue at 30 June 2026). |
“—” = not publicly disclosed.
Directors' Remuneration
| Name | Salary and fees | Cash bonus | Super | Long service leave | Share-based | Total FY2026 | Total FY2025 |
|---|---|---|---|---|---|---|---|
Patrick Cook (Chair) | 43,750 | 0 | 0 | 0 | 40,632 | 84,382 | 4,167 |
Cheri Walker (NED in FY2026) | 50,000 | 0 | 0 | 0 | 29,023 | 79,023 | 50,000 |
Anthony May | 39,063 | 0 | 4,688 | 0 | 20,316 | 64,067 | 4,167 |
John Kelly (MD/CEO) | 396,969 | 28,710 | 30,000 | 20,271 | 0 | 475,950 | 425,791 |
Chandra Sukumar (COO) | 274,015 | 59,625 | 30,000 | 10,145 | 0 | 373,785 | 316,857 |
Total KMP | 803,797 | 88,335 | 64,688 | 30,416 | 89,971 | 1,077,207 | 1,042,648 |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
2 May 2025 | Cook and May appointed; John Keith (Chair), Paul Kasian and Deborah Neff resign | Board renewal to "lean up the board" and support reduced opex (FY2025 results call) |
23 May 2025 | Kelly appointed Interim Chair | Continuity pending independent chair |
9 Sep 2025 | Cook appointed Chair; Kelly steps down as Interim Chair | Governance normalisation |
19 Aug 2026 | Kelly steps down as MD/CEO and director; Walker appointed Interim CEO | Board decision to "reposition" executive leadership closer to US and European markets; formal global CEO search commenced |
| — | NED "C LaBelle" resigned (Final Director's Interest Notice) | — |
Major Shareholders
| Holder | Shares | Approx. % of 902.4m shares | Basis / date |
|---|---|---|---|
GZ Family Holdings Pty Ltd | 89,895,644 | ~10.0 | Simply Wall St register data (2025); substantial holder history from 2023 |
John Kelly (co-founder, former MD) | 74,111,870 | ~8.2 | FY2026 Annual Report (KMP disclosure) |
Dalraida Holdings Pty Limited | 65,120,000 | ~7.2 | Simply Wall St (2025) |
Global Health Funds, Inc. (Global Health Investment Fund) | ~61,570,716 | ~6.8 | Simply Wall St VC/PE category (2025) |
Lin Xiaoyi | 11,880,000 | ~1.3 | Placement participation, 3 Jul 2025 |
Australia West Holdings Pty Ltd | 10,550,000 | ~1.2 | Placement participation, 3 Jul 2025 |
Australia North Holdings Pty Ltd | 10,002,433 | ~1.1 | Placement participation, 3 Jul 2025 |
Competitive Landscape
Competitors by Segment
| Business line | Competitor | HQ | Competing product(s) | Relative positioning vs Atomo |
|---|---|---|---|---|
HIV self-test | OraSure Technologies (NASDAQ: OSUR) | US | OraQuick HIV Self-Test (oral fluid) | Market leader in HIV self-testing; oral sample avoids finger-stick; far larger scale |
HIV self-test / professional | Abbott Laboratories (NYSE: ABT) | US | Determine HIV, other rapid tests (ex-Alere) | Dominant global rapid test supplier; scale, tender pricing power |
HIV self-test / professional | bioLytical Laboratories | Canada | INSTI HIV Self Test and professional test | Direct blood-based self-test competitor in developed markets and LMICs |
HIV self-test (Europe) | Biosynex (Euronext Growth) | France | Exacto / autotest VIH | Direct European retail competitor; also owns Chembio |
HIV / syphilis | Chembio Diagnostics (now part of Biosynex) | US | DPP HIV-Syphilis, DPP Syphilis Screen & Confirm | Combined treponemal/non-treponemal syphilis capability competes with Atomo's Active Syphilis |
HIV / syphilis | Trinity Biotech (NASDAQ: TRIB) | Ireland | Uni-Gold HIV, syphilis rapid tests | Professional HIV rapid tests in LMIC tenders |
HIV / syphilis / broad RDT | SD Biosensor | South Korea | SD Bioline HIV, syphilis and duo tests | Low-cost high-volume Asian RDT manufacturer |
Broad RDT / LMIC | Premier Medical Corporation, Wondfo, other Asian manufacturers | India / China | HIV and syphilis RDTs | Price competition in donor-funded tenders |
OEM lateral-flow devices and contract manufacturing | Abingdon Health | UK | Lateral-flow contract development and manufacturing | Competes for OEM partners seeking development and manufacturing |
Integrated sample-to-result POC devices | Various (e.g., in-house cassette designs at IVD companies) | Global | Proprietary cassettes, capillary collection devices | Partners may develop in-house rather than license Pascal |
Peer Comparison FY2026
| Metric | Atomo (FY2026, AUD) | OraSure (FY2024, USD) | Abbott (FY2024, USD) |
|---|---|---|---|
Revenue | A$5.3m | ~US$186m | ~US$42bn (group) |
Revenue growth | +41% | — | — |
Gross margin | 35% | — | — |
R&D intensity (P&L line) | 14% | — | — |
Profitability | Loss-making | — | Profitable |
Recent Developments
--



